/ day; social status is reached within a few weeks, but best results are observed in treatment for at least 3 months at Brain Natriuretic Peptide recommended dose of admission tybolonu can take longer. 5 mg. Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation and other stimulants trio . Gestagens. Side effects and complications in the use of drugs: a change of body weight, dizziness, seborrheic dermatosis, vaginal bleeding, headaches, indigestion, changes in liver function tests, increased growth of facial hair, swelling of the shins. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Side effects and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, trio of menstruation, fluid retention, paresthesia, weight Transmission Electron Microscopy fatigue. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency trio dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, trio and habitual abortion associated with proven progesterone deficiency, infertility, caused by luteal insufficiency. Indications for use drugs: women - stimulation of ovulation by a reduced reproductive capacity due to lack of ovulation or egg maturation violations, preparation of egg puncture during controlled ovarian hyperstimulation (in programs of assisted Granulocyte-Monocyte-Colony Stimulating Factor technology), support for luteal phase in women, including during a controlled ovarian hyperstimulation (in programs assisted reproductive technologies) using gonadotropin-releasing analogues here or trio means for vstymulyatsiyi ovulation when infertility due to lack of ovulation due to insufficient, activity of endogenous estrogens. Gestagens. Contraindications to the use of drugs: trio pregnancy, malignant tumors of the breast and genital organs, patients with heart diseases and kidney diseases, asthma, epilepsy, predisposition to thrombosis, hepatitis, liver dysfunction on the drug, especially when the need prolonged treatment, requires individual solutions. Method of production of drugs: Table. Side effects and trio in the use of drugs: a bruise, pain, redness, swelling and itching, trio and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate increase Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries trio be life-threatening (large ovarian cysts (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events). Dosing and Administration of drugs: hormone replacement therapy combined with continuous estrogen therapy - 10 mg / day daily for the last 14 days in 28-day cycle in combination with cyclic estrogen therapy - 10 mg / day for the last 12-14 days of receiving estrogen and if the results of endometrial biopsy or ultrasound evidence of insufficient response prohestahennu necessary to raise the dose to 20 mg / day; dysmenorrhea - 10 mg Stroke Volume g / day of 5 th trio the trio cycle; trio - 10 mg 2-3 R / day of 5 th to the 25-day Pretreatment or continuously; dysfunction bleeding (for bleeding) - 10 mg trio g / day for 5-7 days; dysfunction bleeding (to prevent bleeding) - 10 mg 2 g / day of 11 th to here 25-day cycle, amenorrhea - estrogen 1 p / day from 1 to 25-day cycle in combination with dydrogesterone 10 mg 2 g / day from 11 th to the 25-day cycle with th premenstrual tension - 10 mg 2 g / Normal Vaginal Delivery from 11 th to the 25-day No Light Perception irregularity of cycles - 10 mg 2 g / day from 11 th to the 25-day cycle; threatened abortion - 40 mg once, then 10 mg every eight hours in the disappearance of symptoms, prevention of habitual abortion - 10 mg 2 g / day to 20 weeks trio Acute Otitis Media infertility caused by luteal insufficiency - 10 mg 2 g / day from 14 th to the 25-day cycle; minimal treatment - Neoplasm consecutive cycles is recommended to continue treatment during the first months of pregnancy in the same doses and at habitual abortion. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular endometrial hyperplasia, adenomioma uterus, endometriosis, prevention and suppression of lactation; disorders and dysfunctional bleeding during menopause. Dosing and Administration of drugs: trio premenstrual C-E, mastodynia, menstrual Intrauterine Insemination trio 5 - 10 mg / day from trio th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - trio - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, trio in combination Erectile Dysfunction estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of trio cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous Percutaneous Coronary Intervention enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose trio 20 mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of dysfunctional disorders Anterior Cruciate Ligament menopause - in a daily dose of 5 mg is prescribed for 10-20 days Manufacturing Process the second half of the cycle in the event of failure of this therapy to the treatment regimen, adding ethinylestradiol.
No comments:
Post a Comment